Skip to main content
Premium Trial:

Request an Annual Quote

Tegal Gets Shareholder OK to Change Name to CollabRx

NEW YORK (GenomeWeb News) – Tegal said after the close of the market yesterday that it has received approval from its shareholders to change the name of the firm to CollabRx.

The name change comes a couple of months after Tegal completed its purchase of genomics data analysis firm CollabRx for an undisclosed amount. At the time, Tegal had said that it would ask its shareholders to approve the name change.

As of tomorrow, the firm's shares will trade on the Nasdaq under the ticker symbol CLRX.

Tegal develops new and emerging technologies with a current focus on technologies in the medical device and healthcare segments. CollabRx offers cloud-based systems to inform healthcare decision-making using genomics-based medicine.

Each firm's CEO — Thomas Mika of Tegal and James Karis of CollabRx — are serving as co-CEOs of the San Francisco-based firm. Mika continues to serve as chairman.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.